Absci Advances Zero-Shot De Novo AI-Designed Antibody Programs and Expands Biopharma Partnerships
November 3, 2026 • Source: BioSpace
Absci reported preclinical and clinical progress across its de novo AI-designed antibody portfolio including ABS-101 (anti-TL1A) and oncology collaborations with AstraZeneca and Memorial Sloan Kettering.
**Executive Summary (2026-11-03):** Absci reported preclinical and clinical progress across its de novo AI-designed antibody portfolio including ABS-101 (anti-TL1A) and oncology collaborations with AstraZeneca and Memorial Sloan Kettering. Source: BioSpace.
Technical Architecture & R&D Impact
Using its Integrated Drug Creation platform and SoluPro E. coli screening assay, Absci validates millions of AI-designed HCDR3 variants per week for affinity, developability, and manufacturability.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Clinical Readout category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published November 3, 2026
More NewsLast updated: November 3, 2026
